Category: Genentech

Clay Siegall Does His Bit For The Environment Too

Clay Siegall wants to promote “cover crops” that tolerate cooler weather. These can be grown on fields once their crops have been harvested. These plants play very effective roles. They help to keep soil in place. They also ensure that nutrients do not escape these fields. Besides, these nutrients do not move out and pollute the streams nearby.

But the average farmer is still not keen for these crops so much. But Clay Siegall feels that farmers can be motivated to cover their fields. This can happen if they are paid a lot of money for doing this. This has already worked well in Maryland.

Basically, cover crops are able to pay for themselves. This is because they are able to keep soil healthy as valuable nutrients are kept in the field only. This means that the farmers will not have to spend that much money on buying fertilizer or so much energy on spreading it in their fields.

Farmers are basically reluctant towards planting cover crops as they find it extra work. Hence generous payments are required in order to convince them to plant these cover crops.

It was in 1998 that Clay Siegall had become the founder of Seattle Genetics along with others. He is the President of the company today. Additionally, he is also the Chief Executive Officer of the company today. Clay Siegall is on its Board of Directors too. Seattle Genetics has developed a portfolio that is quite diverse. It targets cancer along with autoimmune indications. Clay Siegall has made Seattle Genetics a leading company in antibody technologies.

The company is managing its activities for raising capital pretty well. They have already managed to secure over $330 million. Both public, as well as private financings, have been responsible for this. There have been multiple collaborations that include an exclusive agreement with Genentech for SGN-40. This is a global collaboration that is valued above $860 million. In addition, there have been a number of ADC collaborations. These have been with Genentech, MedImmune as well as CuraGen. Other companies include Bayer as well as Progenics. Over $65 million has been generated this way.